Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis

[1]  R. Falk,et al.  Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. , 2015, Circulation. Heart failure.

[2]  I. Merkies.  Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.

[3]  Yukio Ando,et al.  Guideline of transthyretin-related hereditary amyloidosis for clinicians , 2013, Orphanet Journal of Rare Diseases.

[4]  F. Salvi,et al.  Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. , 2013, European heart journal.

[5]  R. Labaudinière,et al.  Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.

[6]  B. Ericzon,et al.  Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[7]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[8]  H. Katus,et al.  Serum levels of NT-proBNP as surrogate for cardiac amyloid burden: new evidence from gadolinium-enhanced cardiac magnetic resonance imaging in patients with amyloidosis , 2009, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[9]  M. Borggrefe,et al.  Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema. , 2009, International journal of cardiology.

[10]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.

[11]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  S. Ikeda,et al.  Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: outcomes of living donor liver transplantations. , 2005, Internal medicine.

[13]  Peter J Dyck,et al.  Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. , 2005, Diabetes care.

[14]  R. Falk,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.

[15]  A. Vinik,et al.  The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. , 2005, Diabetes technology & therapeutics.

[16]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[17]  B. Ericzon,et al.  Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry , 2004, Transplantation.

[18]  O. Leone,et al.  Combined heart and liver transplantation for familial amyloidotic polyneuropathy. , 2003, The Journal of thoracic and cardiovascular surgery.

[19]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[20]  Catherine E Costello,et al.  Tabulation of human transthyretin (TTR) variants, 2003 , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[21]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  O. Suhr,et al.  Long‐term follow‐up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type) , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  J. Kelly,et al.  Trans-Suppression of Misfolding in an Amyloid Disease , 2001, Science.

[24]  M. Saraiva.  Transthyretin amyloidosis: a tale of weak interactions , 2001, FEBS letters.

[25]  M. Saraiva.  Transthyretin mutations in hyperthyroxinemia and amyloid diseases , 2001, Human mutation.

[26]  H. Ideta,et al.  A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. , 1999, Biochemical and biophysical research communications.

[27]  P. Nihoyannopoulos,et al.  Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. , 1998, Transplantation.

[28]  D. Lewis,et al.  Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. , 1997, Transplantation.

[29]  W. Litchy,et al.  Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort , 1997, Neurology.

[30]  A. Sousa,et al.  Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy , 1996, Neuromuscular Disorders.

[31]  W. Litchy,et al.  Variables influencing neuropathic endpoints , 1995, Neurology.

[32]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[33]  G. Holmgren,et al.  Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy , 1994, Journal of internal medicine.

[34]  R. Falk,et al.  Liver Transplantation as a Treatment for Familial Amyloidotic Polyneuropathy , 1994, Annals of Internal Medicine.

[35]  G. Holmgren,et al.  Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) , 1991, Clinical genetics.

[36]  S. Araki,et al.  Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy. , 1986, Journal of biochemistry.

[37]  C. Blake,et al.  Strjcture of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. , 1974, Journal of molecular biology.

[38]  D. Small,et al.  Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. , 2007, The FEBS journal.

[39]  It Istituto Superiore di Sanit,et al.  Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from th 10th International Symposium on Amyloid an Amyloidosis, Tours, France, 18-22 April 2004 , 2005 .

[40]  S M Breathnach,et al.  Amyloid and amyloidosis. , 1988, Journal of the American Academy of Dermatology.

[41]  P. Coutinho,et al.  Forty years of experience with type I amyloid neuropathy. Review of 483 cases , 1980 .

[42]  O. M. Vinogradova,et al.  [Familial amyloidosis]. , 1975, Klinicheskaia meditsina.